At a glance
ClinicalIndex Comparison RecordN/ACompleted· 474 enrolled
Drug / intervention
Scoring tool in Chemotherapy-induced necrosis in Ewing sarcomabehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Chemotherapy-induced Necrosis in Ewing Sarcoma: Which is the Best Scoring Tool
In Brief
An observational study evaluating Scoring tool in Chemotherapy-induced necrosis in Ewing sarcoma for Ewing Sarcoma of Bone. Completed, enrolled 474 participants across 1 site.
Detailed Summary
This is single institution cases series review of histological and clinical data
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsEwing Sarcoma of Bone
CountriesItaly
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
Enrollment StartMay 2019
First PostedMay 2019
Primary CompletionDec 2019
Study CompletionJan 2020
TodayJul 2026
First PostedMay 30, 2019
Enrollment StartMay 13, 2019
Primary CompletionDec 31, 2019
Study CompletionJan 15, 2020
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 7.1 years ago
Interventions
Scoring tool in Chemotherapy-induced necrosis in Ewing sarcomabehavioral
The aim of the present study is to evaluate which is the best scoring tool to determine the histological response to chemotherapy in localized Ewing sarcoma of bone. The study will exam all the different systems to evaluate the histological necrosis after neo-adjuvant chemotherapy in all patients with localized Ewing sarcomas of bone surgically treated between 1982 and 2012.